Everything You Need. Nothing You Don't.

AI-powered clinical documentation with revenue optimization built in.

Capture 10-15% More Revenue

NovaScribe identifies billable services you might miss, optimizes your MDM documentation, and validates diagnosis codes automatically.

CPT Code Suggestions

Auto-detects billable counseling and time-based services. See wRVU values and dollar estimates. One-click insert adds supporting documentation to your note.

ICD-10 Validation

Extracts diagnosis codes with CMS validation. Flags when codes need more specificity. Copy all codes or use Epic-specific format with one click.

MDM Optimization

Our MDM engine analyzes your note against CMS guidelines. Suggests when your documentation supports a higher E/M level with the wRVU difference displayed.

Everything Ready Before the Next Patient

Streamline your workflow with tools that extract exactly what you need from each encounter.

Orders Checklist

All medication changes and orders extracted as a color-coded checklist. NEW, CHANGE, and STOP badges make it easy to enter orders in your EHR.

Patient Instructions

Auto-generates checkout handout in patient-friendly language. Follow-up appointments, medication changes, and warning signs—ready to print or paste.

Current Evidence for the Patient in Front of You

Ask any clinical question and get an AI-synthesized answer drawn from practice guidelines, systematic reviews, and randomized controlled trials -- with every reference verified and linked to the original source.

Guidelines First
Prioritizes clinical practice guidelines and high-impact systematic reviews over general literature
AI-Synthesized Evidence
Key findings distilled into actionable summaries with evidence strength grading
Verified References
Every citation links to the original peer-reviewed source -- zero hallucinated references
Heart failure CKD Type 2 DM
Strong Evidence
SGLT2 inhibitors (empagliflozin, dapagliflozin) reduce heart failure hospitalization and cardiovascular death in HFrEF patients regardless of diabetes status. Benefits persist in CKD stage 3 with eGFR as low as 20 mL/min.
McMurray et al., NEJM 2019 (DAPA-HF) | Packer et al., NEJM 2020 (EMPEROR-Reduced)
Moderate Evidence
Initial eGFR decline of 3-5 mL/min is expected and reversible. Long-term renal trajectory is preserved or improved compared to placebo. AHA/ACC guidelines recommend SGLT2i as first-line in HFrEF (Class I, Level A).
Heerspink et al., NEJM 2020 (DAPA-CKD) | 2022 AHA/ACC HF Guidelines
AI-generated summaries from published literature. Always verify before clinical use.

Evidence Mode: Proof Your Note is Real

Every sentence in your AI-generated note can be traced back to the original transcript. Hover over any line to see the exact source. No hallucinations. No fabrications. Built for medicolegal confidence.

Built by a Physician Who Needed Proof

Simple, Transparent Pricing

No hidden fees. Start free and upgrade when you need more.

Free
$0
forever
10 notes/month
All AI features
Basic
$99/mo
or $999/year (save 16%)
Unlimited notes
Premium AI quality
Professional
$229/mo
or $2,299/year (save 17%)
Unlimited notes
+ Billing optimization
View full comparison →

Ready to Try NovaScribe?

10 notes per month free. No credit card required.

Start Your Free Trial